I Survived the SCOPE Summit … and Have Key Takeaways to Prove It
Article
Clinical
A unicorn protocol is really pretty and it sparkles, but … you can’t recruit for one of those.
著者について
Darcy Grabenstein
Director of Content Strategy and Thought Leadership | Citeline
Darcy is the Director of Content Strategy and Thought Leadership for Citeline. A journalist by training, she has more than 30 years of experience in marketing, advertising, and public relations.
FAQ
What were the biggest themes at the SCOPE Summit this year?
Dominant themes included patient-centricity, data quality and integration, patient recruitment challenges, the expanding role of AI, and clinical trial diversity. Across sessions, speakers emphasized moving from theory to execution, particularly in how sponsors design protocols, use real-world data, and engage patients more effectively.
How is patient-centricity being measured and applied in clinical research today?
Patient-centricity is no longer just aspirational — it’s being actively evaluated and implemented. At SCOPE, it was highlighted as a new scoring dimension in the Good Pharma Scorecard, alongside transparency, data sharing, access to medicines, and DEI.
Why does patient recruitment remain such a major challenge for clinical trials?
Recruitment continues to be a bottleneck due to overly restrictive or unrealistic protocols, limited visibility into where eligible patients are, and logistical barriers for participants. A feasibility informed, data-driven approach — one that balances protocol rigor with real-world enrollment realities — is essential.
